National Clinical Trials Network and National Cancer Institute Community Oncology Research Program lymphoma and leukemia trials open at time of submission
| Protocol number . | Phase . | Diagnosis . | Age . | Drugs . | Group . |
|---|---|---|---|---|---|
| Leukemia | |||||
| A041501 | 3 | Newly diagnosed CD22+, Ph negative precursor B-ALL | 18-39 years | Inotuzumab ozogamicin | ALLIANCE COG ECOG-ACRIN NGR SWOG CCTG |
| AALL1821 | 2 | First relapse B-ALL | 1 to 30 years | Blinatumomab and nivolumab | COG ECOG-ACRIN NGR SWOG ALLIANCE |
| Lymphoma | |||||
| A051901 | 1 | Primary CNS lymphoma | 18 years and older | Lenalidomide and nivolumab | ALLIANCE |
| A051902 | 2 | CD30 negative peripheral T-cell lymphoma | 18 years and older | Duvelisib and CC-486 (azacitidine) | ALLIANCE ECOG-ACRIN NGR SWOG |
| ANHL1931 | 3 | Newly diagnosed primary mediastinal B-cell | 2 years and older | Nivolumab | COG ALLIANCE ECOG-ACRIN NGR SWOG |
| AHOD2131 | 3 | Newly diagnosed stage I and II classical Hodgkin lymphoma | 5 to 60 years | Brentuximab vedotin and nivolumab | COG ALLIANCE ECOG-ACRIN NGR SWOG |
| E4412 | 1/2 | Relapsed/refractory Hodgkin lymphoma | 18 years and older | Ipilimumab, nivolumab, and brentuximab vedotin | ECOG-ACRIN COG ALLIANCE NGR SWOG |
| Multiple diagnoses | |||||
| ACCL1931 | 3 | Newly diagnosed B-ALL, T-ALL, LLy, MPAL | 15 to 39 years | Levocarnitine | COG ALLIANCE ECOG-ACRIN SWOG |
| ACCL21C2 | Other | Any cancer diagnosis | 6 months to 36 years | COVID-19 vaccine | COG ALLIANCE ECOG-ACRIN NGR SWOG |
| Protocol number . | Phase . | Diagnosis . | Age . | Drugs . | Group . |
|---|---|---|---|---|---|
| Leukemia | |||||
| A041501 | 3 | Newly diagnosed CD22+, Ph negative precursor B-ALL | 18-39 years | Inotuzumab ozogamicin | ALLIANCE COG ECOG-ACRIN NGR SWOG CCTG |
| AALL1821 | 2 | First relapse B-ALL | 1 to 30 years | Blinatumomab and nivolumab | COG ECOG-ACRIN NGR SWOG ALLIANCE |
| Lymphoma | |||||
| A051901 | 1 | Primary CNS lymphoma | 18 years and older | Lenalidomide and nivolumab | ALLIANCE |
| A051902 | 2 | CD30 negative peripheral T-cell lymphoma | 18 years and older | Duvelisib and CC-486 (azacitidine) | ALLIANCE ECOG-ACRIN NGR SWOG |
| ANHL1931 | 3 | Newly diagnosed primary mediastinal B-cell | 2 years and older | Nivolumab | COG ALLIANCE ECOG-ACRIN NGR SWOG |
| AHOD2131 | 3 | Newly diagnosed stage I and II classical Hodgkin lymphoma | 5 to 60 years | Brentuximab vedotin and nivolumab | COG ALLIANCE ECOG-ACRIN NGR SWOG |
| E4412 | 1/2 | Relapsed/refractory Hodgkin lymphoma | 18 years and older | Ipilimumab, nivolumab, and brentuximab vedotin | ECOG-ACRIN COG ALLIANCE NGR SWOG |
| Multiple diagnoses | |||||
| ACCL1931 | 3 | Newly diagnosed B-ALL, T-ALL, LLy, MPAL | 15 to 39 years | Levocarnitine | COG ALLIANCE ECOG-ACRIN SWOG |
| ACCL21C2 | Other | Any cancer diagnosis | 6 months to 36 years | COVID-19 vaccine | COG ALLIANCE ECOG-ACRIN NGR SWOG |
Lead group is in bold.
ALL, acute lymphoblastic leukemia; CCTG, Canadian Cancer Trials Group; CNS, central nervous system; ECOG-ACRIN, ECOG-ACRIN Cancer Research Group (merger of Eastern Cooperative Oncology Group (ECOG) and American College of Radiology Imaging Network (ACRIN)); LLy, lymphoblastic lymphoma; MPAL, mix phenotype acute leukemia; NGR, NRG Oncology (merger of National Surgical Adjuvant Breast and Bowel Project (NSABP), the Radiation Therapy Oncology Group (RTOG), and Gynecologic Oncology Group (GOG)).